Gamma-aminobutyric acid type A receptor alpha-5 subunit-containing subtype (α5-GABAAR)

The Gamma-aminobutyric acid type A (GABAA) receptor alpha-5 subunit-containing subtype is a pentameric ligand-gated ion channel that plays a specialized role in the central nervous system. Unlike the more common α1, α2, and α3 subtypes that mediate fast phasic inhibition at synapses, α5-containing receptors are primarily located extrasynaptically in the hippocampus and cortex, where they mediate tonic inhibition (Source: Frontiers in Pharmacology, 2019). This tonic conductance is a key regulator of neuronal excitability and synaptic plasticity, making the α5 subtype a critical determinant of cognitive functions such as learning and memory (Source: NIH, 2024). Dysfunction of this receptor subtype is linked to several conditions, including Alzheimer's disease, Down syndrome, schizophrenia, and major depressive disorder (Source: PubMed, 2024). Therapeutic strategies involve negative allosteric modulators (NAMs) to enhance cognition by reducing tonic inhibition, and positive allosteric modulators (PAMs) to provide anxiolytic or antidepressant effects by enhancing it (Source: Biorxiv, 2024). Because of its restricted expression pattern, targeting the α5 subtype offers the potential for cognitive enhancement or mood regulation with a lower risk of the sedation and motor impairment typically associated with non-selective benzodiazepines (Source: Wikipedia, 2024).

Other names

GABRA5-containing GABAA receptorAlpha-5 GABAA receptorGABAA receptor alpha-5 subtypeα5-GABAA receptorGABRA5 receptor

Positive and negative allosteric modulation of the GABAA receptor chloride channel, typically at the benzodiazepine binding site (alpha+/gamma2- interface) or the alpha+/beta- interface.